日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

PROX1 is an early driver of lineage plasticity in prostate cancer.

PROX1 是前列腺癌谱系可塑性的早期驱动因素

Duan Zhi, Shi Mingchen, Kumaraswamy Anbarasu, Lin Dong, Khokhani Dhruv, Wang Yong, Zhang Chao, Flores Diana, Rodansky Eva, Swaim Olivia A, Storck William K, Beck Hannah N, Patel Radhika A, Sayar Erolcan, Hanratty Brian P, Xue Hui, Dong Xin, Maylin Zoe R, Wan Rensheng, Quigley David A, Sjöström Martin, Hu Ya-Mei, Zhao Faming, Xia Zheng, Cheng Siyuan, Yu Xiuping, Feng Felix Y, Zhang Li, Aggarwal Rahul, Small Eric J, Ravikumar Visweswaran, Rao Arvind, Bedi Karan, Lee John K, Morrissey Colm, Coleman Ilsa, Nelson Peter S, Corey Eva, Udager Aaron M, Rebernick Ryan J, Cieslik Marcin P, Chinnaiyan Arul M, Yates Joel A, Haffner Michael C, Wang Yuzhuo, Alumkal Joshi J

Therapeutic Exploitation of Neuroendocrine Transdifferentiation Drivers in Prostate Cancer

前列腺癌中神经内分泌转分化驱动因素的治疗应用

Maylin, Zoe R; Smith, Christopher; Classen, Adam; Asim, Mohammad; Pandha, Hardev; Wang, Yuzhuo

Hybrid Androgen Receptor Inhibitors Outperform Enzalutamide and EPI-001 in in vitro Models of Prostate Cancer Drug Resistance

在体外前列腺癌耐药模型中,混合型雄激素受体抑制剂的疗效优于恩扎卢胺和EPI-001。

Nicolescu, Radu Costin Bizga; Maylin, Zoe R; Pérez-Areales, Francisco Javier; Iegre, Jessica; Pandha, Hardev S; Asim, Mohammad; Spring, David R

Breaking androgen receptor addiction of prostate cancer by targeting different functional domains in the treatment of advanced disease

通过靶向不同功能域来打破前列腺癌的雄激素受体依赖性,从而治疗晚期疾病

Maylin, Zoe R; Nicolescu, Radu Cb; Pandha, Hardev; Asim, Mohammad